Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer
Combination therapy of lenvatinib, a multitargeted tyrosine kinase inhibitor (TKI), plus pembrolizumab, a monoclonal antibody targeting programmed death receptor 1 (PD-1), was recently approved by the Food and Drug Administration for therapy of advanced endometrial cancer. This case series highlight...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-10-01
|
| Series: | Gynecologic Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578923001273 |
| _version_ | 1797743882022158336 |
|---|---|
| author | Clarissa Lam Debra Sarasohn Britta Weigelt Dmitriy Zamarin |
| author_facet | Clarissa Lam Debra Sarasohn Britta Weigelt Dmitriy Zamarin |
| author_sort | Clarissa Lam |
| collection | DOAJ |
| description | Combination therapy of lenvatinib, a multitargeted tyrosine kinase inhibitor (TKI), plus pembrolizumab, a monoclonal antibody targeting programmed death receptor 1 (PD-1), was recently approved by the Food and Drug Administration for therapy of advanced endometrial cancer. This case series highlights three patients with endometrial serous carcinoma who experienced disease stabilization or slow progression on lenvatinib plus pembrolizumab followed by rapid symptomatic growth of disease after lenvatinib discontinuation, and subsequent repeated response and symptom resolution after lenvatinib re-initiation. All patients died of disease complications 3 to 10 months after retreatment with lenvatinib. These observations highlight an important phenomenon of lenvatinib withdrawal rebound, likely driven by oncogenic signaling pathways upregulated in response to lenvatinib therapy. The findings of this case series represent a potential area for further research into the underlying mechanism for rebound and repeated response to lenvatinib, as well as strategies to mitigate disease flare related to lenvatinib withdrawal. |
| first_indexed | 2024-03-12T15:01:52Z |
| format | Article |
| id | doaj.art-d0db035ace3e438eb48633e9306b5b60 |
| institution | Directory Open Access Journal |
| issn | 2352-5789 |
| language | English |
| last_indexed | 2024-03-12T15:01:52Z |
| publishDate | 2023-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gynecologic Oncology Reports |
| spelling | doaj.art-d0db035ace3e438eb48633e9306b5b602023-08-14T04:07:43ZengElsevierGynecologic Oncology Reports2352-57892023-10-0149101258Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancerClarissa Lam0Debra Sarasohn1Britta Weigelt2Dmitriy Zamarin3Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USADepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USADepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USADivision of Gynecological Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Corresponding author at: Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, USACombination therapy of lenvatinib, a multitargeted tyrosine kinase inhibitor (TKI), plus pembrolizumab, a monoclonal antibody targeting programmed death receptor 1 (PD-1), was recently approved by the Food and Drug Administration for therapy of advanced endometrial cancer. This case series highlights three patients with endometrial serous carcinoma who experienced disease stabilization or slow progression on lenvatinib plus pembrolizumab followed by rapid symptomatic growth of disease after lenvatinib discontinuation, and subsequent repeated response and symptom resolution after lenvatinib re-initiation. All patients died of disease complications 3 to 10 months after retreatment with lenvatinib. These observations highlight an important phenomenon of lenvatinib withdrawal rebound, likely driven by oncogenic signaling pathways upregulated in response to lenvatinib therapy. The findings of this case series represent a potential area for further research into the underlying mechanism for rebound and repeated response to lenvatinib, as well as strategies to mitigate disease flare related to lenvatinib withdrawal.http://www.sciencedirect.com/science/article/pii/S2352578923001273Endometrial cancerLenvatinibPembrolizumabLenvatinib addictionRebound response |
| spellingShingle | Clarissa Lam Debra Sarasohn Britta Weigelt Dmitriy Zamarin Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer Gynecologic Oncology Reports Endometrial cancer Lenvatinib Pembrolizumab Lenvatinib addiction Rebound response |
| title | Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer |
| title_full | Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer |
| title_fullStr | Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer |
| title_full_unstemmed | Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer |
| title_short | Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer |
| title_sort | tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer |
| topic | Endometrial cancer Lenvatinib Pembrolizumab Lenvatinib addiction Rebound response |
| url | http://www.sciencedirect.com/science/article/pii/S2352578923001273 |
| work_keys_str_mv | AT clarissalam tumorlenvatinibaddictionandwithdrawalreboundresponseinpatientswithadvancedendometrialcancer AT debrasarasohn tumorlenvatinibaddictionandwithdrawalreboundresponseinpatientswithadvancedendometrialcancer AT brittaweigelt tumorlenvatinibaddictionandwithdrawalreboundresponseinpatientswithadvancedendometrialcancer AT dmitriyzamarin tumorlenvatinibaddictionandwithdrawalreboundresponseinpatientswithadvancedendometrialcancer |